


**Product Name** : PF-06700841  
**Cat. No.** : PC-61819  
**CAS No.** : 1883299-62-4  
**Molecular Formula** : C<sub>18</sub>H<sub>21</sub>F<sub>2</sub>N<sub>7</sub>O  
**Molecular Weight** : 389.411  
**Target** : JAK  
**Solubility** : 10 mM in DMSO



## Biological Activity

PF-06700841 (Brepocitinib, PF 06700841) is a potent dual **JAK1/TYK2** inhibitor with IC<sub>50</sub> of 17/23 nM, inhibits JAK2 and JAK3 with IC<sub>50</sub>=77 and 6494 nM, respectively.

PF-06700841 potently inhibits TYK2/JAK2 mediated IL-12/pSTAT4 and IL-23/pSTAT3 (HWB IC<sub>50</sub>=65 and 120 nM, respectively).

PF-06700841 has good potency against IL6/pStat1 in the CD3+ cellular subset (IC<sub>50</sub> = 81 nM), but lower inhibition of IL6/pSTAT3, again in the CD3+ cellular subset (IC<sub>50</sub>=641 nM).

PF-06700841 inhibits EPO/pSTAT5 (JAK2 homodimer) in HWB spiked with CD34+ progenitor cells (IC<sub>50</sub>=577 nM).

IL10/pSTAT3 (TYK2/JAK1) and IL27/pSTAT3 (JAK1/JAK2/TYK2) are also inhibited by PF-06700841 with IC<sub>50</sub>=305 nM and 86 nM, respectively.

PF-06700841 shows good selectivity against a broad panel of receptors with exception for kinase insert domain receptor (KDR) (VEGFR2) (IC<sub>50</sub>=1600 nM); shows therapeutic effect in the rat adjuvant induced arthritis (AIA) following oral dosing.

## References

Banfield C, et al. *J Clin Pharmacol*. 2017 Dec 21. doi: 10.1002/jcph.1046.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com